The global Viral Vector Manufacturing market, valued at USD 696.17 million in 2022, is projected to grow at a CAGR of 19.22% from 2023 to 2028, reaching USD 1,995.43 million by 2028. This growth is driven by the increasing prevalence of severe genetic disorders, and various cancer types, expanding research in gene and cell therapy, and heightened concerns about epidemics and pandemics during the forecast period from 2023 to 2028. Some of the key Viral Vector Manufacturing companies actively working in the market include Oxford Biomedica, Thermo Fisher Scientific Inc., Quest Diagnostics, Charles River Laboratories, FUJIFILM Diosynth Biotechnologies, Batavia Biosciences, CEVEC Pharmaceuticals GmbH, REGENXBIO Inc., BioNTech IMFS, AGC Biologics, ANDELYN BIOSCIENCES, INSTITUT MERIEUX, IDT Biologika, Lonza, Genezen, NecstGen, Avid Bioservices, Inc., Takara Bio Inc., VIROCELL BIOLOGICS, LTD., and others.
DelveInsight’s “Viral Vector Manufacturing Market Insight, Competitive Landscape and Market Forecast 2028” research report provides the current and forecasted Viral Vector Manufacturing market size, share, and trends analysis for the next five years. Moreover, it highlights the ongoing innovations in the segment, major market drivers & barriers, key competitors, and emerging devices in the domain.
Viral Vector Manufacturing Market: Overview
Viral Vector Manufacturing refers to the process of producing viral vectors, which are modified viruses used as delivery systems in various fields of biotechnology, particularly in gene therapy and vaccine development. Viral vectors are engineered to carry genetic material, such as therapeutic genes or vaccine antigens, into target cells without causing disease. This technology is crucial in the development of cutting-edge therapies and vaccines aimed at treating genetic disorders, certain cancers, and infectious diseases.
The manufacturing process involves several steps, including the propagation of the viral vector in host cells, purification, quality control, and formulation for clinical use. These vectors can be derived from various types of viruses, such as adenoviruses, lentiviruses, and adeno-associated viruses (AAVs). Viral Vector Manufacturing requires stringent safety and quality standards to ensure that the final products are both effective and safe for patients undergoing treatment or vaccination.
To provide a better understanding of the market dynamics, DelveInsight’s “Viral Vector Manufacturing Market” report provides an in-depth assessment of the market by type (adenoviral vectors, adeno-associated viral (AAV) vectors, lentiviral vectors, and others), application (gene therapy, cell therapy, and vaccines), and end-user (research organizations, biotech and pharmaceutical companies, and others).
In the Viral Vector Manufacturing market’s vector type category, adenoviral vectors are anticipated to secure a substantial revenue share in the upcoming years. This is due to the numerous advantages and applications associated with adenovirus vectors. These advantages include versatile tissue targeting, a well-defined genome, ease of genetic modification, ability to accommodate large transgene DNA segments up to 8 kilobases, intrinsic adjuvant properties, capability to stimulate strong transgene-specific T cell and antibody responses, non-replicative nature in the host, and ease of large-scale production. Moreover, Adenoviruses are favored as gene therapy vectors due to their effective cellular uptake in vivo and the reported absence of side effects in vaccines derived from adenoviruses for human use.
Given these advantages and the increasing utilization of adenoviral vectors, this category is projected to contribute significantly to the overall growth of the global Viral Vector Manufacturing market in the forecast period.
The rapid growth of the Viral Vector Manufacturing market can be predominantly attributed to the expanding embrace of gene and cell therapy, with a specific focus on the utilization of viral vectors for the treatment of genetic disorders. This paradigm shift in the approach to genetic disorders has opened up promising avenues for medical interventions that were once considered out of reach.
As per the World Federation of Hemophilia, there were approximately 347,000+ reported cases of bleeding disorders worldwide in 2020. Furthermore, in the same year, there were roughly 209,000+ individuals diagnosed with hemophilia, consisting of 165,000+ cases of hemophilia A, 33,000+ cases of hemophilia B, and 11,000+ cases of hemophilia where the type was either unknown or not reported.
Gene and cell therapy, empowered by viral vectors, represents a transformative approach to tackling genetic disorders at their root cause. These vectors serve as the vehicles for delivering therapeutic genes into patients’ cells, thereby addressing the underlying genetic mutations responsible for various conditions. It’s akin to reprogramming the body’s instruction manual to correct errors that result in diseases. This precision and potential for long-lasting, if not permanent, therapeutic effects are what make gene and cell therapy so compelling.
Due to several benefits, including their ability to efficiently introduce genes into cells, accurately target specific cells, stimulate strong immune responses, and enhance cellular immunity, viral vectors are seen as an appealing and suitable method for cancer treatment. This is especially important in addressing the increasing occurrence of various cancer types, including blood cancer, bladder cancer, and others. Nonetheless, concerns related to the safety of viral vectors and the complexities involved in their production could potentially hinder the expansion of the Viral Vector Manufacturing market as a whole.
Interested to know more about the ongoing developments in the market? Visit to get an in-depth insight @ Viral Vector Manufacturing Types and Emerging Products
Among all the regions, North America is projected to hold the largest portion of the overall Viral Vector Manufacturing market share in the upcoming years. This is attributed to several crucial growth drivers, including a growing patient population with genetic disorders, and a rising prevalence of cancer. According to the National Center on Birth Defects and Developmental Disabilities at the CDC in 2022, sickle cell anemia affects around 100,000 Americans, while Hemophilia A impacts 1 in 5,000 male births, resulting in approximately 400 babies born with the condition annually in the United States. Furthermore, there are 57,000 new cases of bladder cancer in men and 18,000 in women each year in the United States. The Global Cancer Observatory reported 80.6 thousand cases of bladder cancer in the US in 2020, with an anticipated increase to 122 thousand cases by 2040. Consequently, the Viral Vector Manufacturing market is anticipated to experience substantial expansion in this region owing to the rise in the number of cases of genetic disorders and the growth in the prevalence of cancer cases in the region.
Furthermore, advanced healthcare infrastructure, a range of strategic initiatives related to Viral Vector Manufacturing in the United States, the presence of major industry players, and expedited regulatory approvals for new products are expected to contribute to the growth of the Viral Vector Manufacturing market within the forecast period. Hence, the above-mentioned factors are going to increase the growth of the Viral Vector Manufacturing market in the region.
Interested in knowing how the market will grow by 2028? Click to get a snapshot @ Viral Vector Manufacturing Market Trends and Developments
In recent years, the Viral Vector Manufacturing market has undergone substantial evolution, primarily driven by the active engagement of international MedTech firms and notable technological progress in the field. Simultaneously, significant clinical, commercial, and regulatory advancements have been recorded within this domain. Some of the key developments in the Viral Vector Manufacturing sector in recent times are as follows:
- On August 30, 2023, Quest Diagnostics (NYSE: DGX) announced that its AAVrh74 ELISA assay (CDx) has been granted Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA).
- In August 2022, Thermo Fisher Scientific, the world leader in serving science, expanded its cell and gene therapy capabilities with the opening of its new Viral Vector Manufacturing facility in Plainville, Mass.
- In October 2022, Kite, a Gilead Company announced that the US FDA has approved the company’s retroviral vector (RVV) manufacturing facility in Oceanside, California, for commercial production.
- In October 2021, Merck, a leading science and technology company, announced the opening of its second Carlsbad, California-based facility, significantly expanding its global CDMO footprint.
Learn more about major clinical and commercial development in the market @ Viral Vector Manufacturing Market – Clinical and Commercial Development Activities
Globally, some of the leading MedTech giants working in the Viral Vector Manufacturing market include Quest Diagnostics, Oxford Biomedica, Thermo Fisher Scientific Inc., Charles River Laboratories, FUJIFILM Diosynth Biotechnologies, Batavia Biosciences, CEVEC Pharmaceuticals GmbH, REGENXBIO Inc., BioNTech IMFS, AGC Biologics, ANDELYN BIOSCIENCES, INSTITUT MERIEUX, IDT Biologika, Lonza, Genezen, NecstGen, Avid Bioservices, Inc., Takara Bio Inc., VIROCELL BIOLOGICS, LTD., and others. Because of rising demand and the promising potential for revenue generation, it is anticipated that several newcomers will enter the market, leading to intensified competition in the industry.
Learn how new players’ entries will transform the market dynamics in the coming years @ Viral Vector Manufacturing Competitive Landscape
Scope of the Viral Vector Manufacturing Market Report:
- Study Period – 2020-2028
- Geography Covered – North America, Europe, Asia-Pacific, and Rest of the World
- Viral Vector Manufacturing Market Assessment by –
-
-
- Type – Adenoviral Vectors, Adeno-Associated Viral (AAV) Vectors, Lentiviral Vectors, and Others
- Application – Gene Therapy, Cell Therapy, and Vaccines
- End-User – Research Organizations, Biotech and Pharmaceutical Companies, and Others
-
- Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s Views
Table of Content
| 1 | Report Introduction |
| 2 | Executive Summary |
| 3 | Regulatory and Patent Analysis |
| 4 | Viral Vector Manufacturing Market Key Factors Analysis |
| 5 | Viral Vector Manufacturing Porter’s Five Forces Analysis |
| 6 | COVID-19 Impact Analysis on the Viral Vector Manufacturing Market |
| 7 | Viral Vector Manufacturing Market Layout |
| 8 | Viral Vector Manufacturing Global Company Share Analysis – Key 3–5 Companies |
| 9 | Viral Vector Manufacturing Product Profiles and Key Companies |
| 10 | Project Approach |
| 11 | KOL Views |
| 12 | DelveInsight Capabilities |
| 13 | Disclaimer |
| 14 | About DelveInsight |
Reach out to us to get a more detailed overview of the market @ Viral Vector Manufacturing Market Insights and Competitive Landscape
Elevate your industry insights with our comprehensive medical devices market assessment reports. Visit to gain a strategic edge through expert analysis and in-depth coverage of the latest trends, innovations, and market dynamics, at: Medical Devices Market Research
Other Trending Healthcare Reports by DelveInsight:
Aneurysmal Subarachnoid Hemorrhage (SAH) Market | Dupuytren’s Disease Market | Homocystinuria Market | Platinum-Resistant Relapsed Ovarian Cancer Market | Dementia with Diabetes Market | Pyruvate Kinase Deficiency Market | Uterine Serous Carcinoma Market | Paraganglioma Market | Spinal Cord Stimulators (SCS) Global Market | Adult Spinal Deformity Market | Age-related Vision Dysfunction Market | Erythropoietic Protoporphyria Market | Juvenile Idiopathic arthritis (JIA) Market | Cerebral Vein Thrombosis Market | Hearing Aid Devices Market | Cardiotoxicity Market | Aortic Aneurysm Stent Grafts Market | Advanced Renal Cell Carcinoma Market | Angioedema Market | Anterior Cruciate Ligament Injuries Market | Chronic Pruritus Market | Pain Management Devices Market | Bone Anchored Hearing Systems Market | Colorectal Cancer Crc Market | Postsurgical Pain Market | Pulse Oximeters Market | Cervical Intraepithelial Neoplasia Market | Chemotherapy Induced Anemia Market | 3d Cardiac Mapping System Market | Alopecia Areata Market | Anaphylaxis Market | Cardiac Amyloidosis Market | Chronic Cutaneous Ulcer Market | Cutaneous T-cell Lymphoma Market | Vertigo Market | Acute Coronary Syndrome Market | Anal Cancer Market | Chemotherapy Induced Thrombocytopenia Market | Cluster Headaches Market | Hearing Implants Market | Hyperhidrosis Market | Nsclc Market
Discover DelveInsight’s Comprehensive Market Research and Consulting Services @ Healthcare Market Research
DelveInsight’s specialized oncology consulting solutions empower the pharma and biotech giants with tailored guidance and forefront proficiency, enabling adept navigation of ever-evolving clinical, commercial, and regulatory landscapes. Explore the key services and solutions @ Oncology Consulting Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Contact Us
Shruti Thakur
Manager (Marketing & Branding)
+1(919)321-6187.
